Brian Shuch, MD, of UCLA Health, shares the key takeaways from his SUO 2024 presentation on advancements in molecular imaging and theranostics for kidney cancer. Dr. Shuch highlights the potential of cutting-edge technologies, like CA9-based imaging and zirconium-labeled girentuximab, in improving diagnostic accuracy and treatment planning. He also discusses how these developments mirror successes in prostate cancer and explores theranostic strategies that could revolutionize care by combining targeted imaging with therapeutic approaches.
#kidneycancer #renalcellcarcinoma #urology #oncology #cancerresearch #healthcare
